Gene

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Diagnosis, Xi'an Jiaotong University, Speech, Gene, Congress, Research, Science, Doctor of Philosophy, Marketing, Overseas, International Medical Congress, Psychiatry, Molecular biology, Notifiable disease, SCO, Hypertension, Shanghai Cooperation Organisation, Medicine, Pharmaceutical industry

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".

Key Points: 
  • BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".
  • Alymkadyr Beishenaliev, Minister of Health of the Kyrgyz Republic, Janesh Kane, Deputy Secretary General of the SCO, and 400 medical professionals, academicians and world-renowned scientists attended the congress.
  • At this congress, Tianlong invited Professor Kou Huijuan from the Department of Cardiology of the Second Affiliated Hospital of Xi'an Jiaotong University to give a speech.
  • Tianlong's participation in the medical conferences facilitated international exchange and cooperation in the medical field.

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Diagnosis, Xi'an Jiaotong University, Speech, Gene, Congress, Research, Science, Doctor of Philosophy, Marketing, Overseas, International Medical Congress, Psychiatry, Molecular biology, Notifiable disease, SCO, Hypertension, Shanghai Cooperation Organisation, Medicine, Pharmaceutical industry

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".

Key Points: 
  • BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March in Bishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai Cooperation Organization".
  • Alymkadyr Beishenaliev, Minister of Health of the Kyrgyz Republic, Janesh Kane, Deputy Secretary General of the SCO, and 400 medical professionals, academicians and world-renowned scientists attended the congress.
  • At this congress, Tianlong invited Professor Kou Huijuan from the Department of Cardiology of the Second Affiliated Hospital of Xi'an Jiaotong University to give a speech.
  • Tianlong's participation in the medical conferences facilitated international exchange and cooperation in the medical field.

Eternity Biotech Launches Crowdfunding Campaign on Wefunder to Accelerate Anti-Aging Product Development

Retrieved on: 
Tuesday, April 2, 2024
DNA repair, Gene, The Company, DNA, Research, Growth, Cell division, Apoptosis, Regulation CF

NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.
  • After replicating these results in human cells, Eternity looks to develop this technology and identify a novel candidate in the anti-aging space.
  • "With this campaign, we look to usher in a new era of growth and development for Eternity and within the broader anti-aging sector of life science research," said Joseph Hernandez, Chairman and Chief Executive Officer of Eternity.
  • To learn more about Eternity's technology and participate in this campaign, visit Eternity's page on Wefunder .

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Retrieved on: 
Tuesday, April 2, 2024
TUSC2, Toxicity, LLC2, Gene, Growth, NSCLC, Diabetes, Risk, Patient, Lung, Neoplasm, Glioma, Mouse, Manuscript, Cancer, Pembrolizumab, NPRL2, Lung cancer, Stomach, BioRxiv, Hepatocellular carcinoma, NK, Natural killer T cell

AUSTIN, Texas, April 2, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the Company's non-viral Oncoprex® Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (NSCLC) in a humanized mouse model.

Key Points: 
  • Genprex's Oncoprex® Delivery System is a novel non-viral approach that utilizes lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor genes deleted during the course of cancer development.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.
  • "These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies," said Rodney Varner, President, Chairman and Chief Executive Officer at Genprex.
  • In conclusion, researchers reported that NPRL2 gene therapy induces anti-tumor activity through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

Retrieved on: 
Tuesday, April 2, 2024
Cell engineering, Immunotherapy, Partnership, Library, Research, DNA, Gene, Acquisition, Society, Wisconsin Alumni Research Foundation, Therapy, Modulus, Safety, Poster, SITC, Cell, WARF, Autoimmunity, Annual general meeting, Vaccine

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.

Key Points: 
  • Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
  • In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors.
  • Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date.
  • Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Tuesday, April 2, 2024
Gene, Artesunate, NMPA, Fosun International, Growth, Cell, Carcinoma, Patient, MSCI, FTG, Rehabilitation, Fosun Pharma, World Health Organization, National Medical Products Administration, Club Med, HKEX, Sustainability, Marketing, SCLC, HSI, AA

During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Tuesday, April 2, 2024
Gene, Artesunate, NMPA, Fosun International, Growth, Cell, Carcinoma, Patient, MSCI, FTG, Rehabilitation, Fosun Pharma, World Health Organization, National Medical Products Administration, Club Med, HKEX, Sustainability, Marketing, SCLC, HSI, AA

During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.